Navigation Links
Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, August 3, 2009
Date:7/29/2009

SAN DIEGO, July 29, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report second quarter 2009 financial results after the NASDAQ Global Market closes on Monday, August 3, 2009. That same afternoon, Jack Lief, Arena's President and Chief Executive Officer, and Robert E. Hoffman, Arena's Vice President, Finance and Chief Financial Officer, will host a conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the financial results for the second quarter 2009 and to provide a business and financial update.

The conference call may be accessed by dialing 877.397.0235 for domestic callers and 719.325.4881 for international callers. Please specify to the operator that you would like to join the "Arena Pharmaceuticals' Second Quarter 2009 Earnings Call." The conference call will be webcast live under the investor relations section of Arena's website at www.arenapharm.com, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for weight management. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck & Co., Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the timing, success and cost of Arena's lorcaserin program and other of its research and development programs; results of clinical trials or preclinical studies may not be predictive of future results; clinical trials and studies may not proceed at the time or in the manner Arena expects or at all; Arena's ability to partner lorcaserin or other of its compounds or programs; the timing and ability of Arena to receive regulatory approval for its drug candidates; Arena's ability to obtain additional funds; Arena's ability to obtain and defend its patents; and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

    Contacts:      Jack Lief
                   President and Chief Executive Officer

                   Cindy McGee
                   Senior Communications Associate

                   Arena Pharmaceuticals, Inc.
                   858.453.7200, ext. 1479


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AHIMA Enters Multinational Arena to Support HIM Worldwide Advancement
2. Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
3. Arena Pharmaceuticals Announces Public Offering of Common Stock
4. Cinergy Health Commentary On President Obamas Call for Cost Control, Competition in Health Insurance Arena
5. Arena Pharmaceuticals to Present at the Piper Jaffray Fourth Annual Europe Conference
6. Arena Pharmaceuticals to Receive $100 Million from Deerfield Management
7. New arenavirus discovered as cause of hemorrhagic fever outbreak in South Africa and Zambia
8. Arena Pharmaceuticals to Present at the 34th Annual Deutsche Bank Health Care Conference
9. Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints
10. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2008 Financial Results and to Host Conference Call and Webcast on Thursday, March 12, 2009
11. Arena Pharmaceuticals Announces Initiation by Merck of Phase 2 Clinical Trial of Niacin Receptor Agonist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... 2016 , ... Bluvault ( Bluvault Inc. ) today announced ... clients of Coupa ( Coupa Software ) and other Cloud software, powered by ... component in the suite of innovative implementation services offered by Bluvault. , "Our ...
(Date:5/6/2016)... ... May 06, 2016 , ... Online HR/benefits platforms offer a range of benefits ... traditional brokers and health plans. “ The Rapid Emergence of Online Benefits Firms: Strategies ... Services, Inc. (AIS), will offer an accurate picture of online benefits today, and the ...
(Date:5/6/2016)... ... May 06, 2016 , ... The International Yoga Teacher Training schoo ... the island close to the town famous for its sunsets, Oia. This all inclusive ... continue to have an amazing experience in Greece, we just can’t stay away” says ...
(Date:5/6/2016)... ... May 06, 2016 , ... Few events in healthcare ... mostly for its cost despite its potential to wipe out a silent killer, ... of a class called direct-acting antivirals (DAAs)—have created fallout in the courts and ...
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... “ Crossing ... Press) shares accounts of dying patients who have allowed those holding vigil to glimpse ... Kuykendall, RN, BSN, CHPN, hopes to help readers spiritually and practically gain insight into ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... May 5, 2016 , First quarter ... revenues of $964 million , First quarter ... $0.40 , Company revises 2016 financial guidance; ... $4.03 billion and 2016 adjusted diluted non-GAAP earnings per share ... Company provides updates regarding Generics business and manufacturing facility restructuring ...
(Date:5/5/2016)... May 5, 2016  Diagnostic imaging has been ... to concerns that these tests cause health care costs to ... imaging, as well as the adoption of new ... medical peripherals that help health care providers cut costs, while ... medical imaging is a renowned authorized reseller of the ...
(Date:5/5/2016)... 2016 Research and Markets has announced the ... 5 EU Markets"  report to their offering.  ,     (Logo: ... on the current Positron Emission Tomography (PET) scanner and cyclotron ... which includes France , Germany ... and the United Kingdom . ...
Breaking Medicine Technology: